S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
NASDAQ:KZIA

Kazia Therapeutics Stock Forecast, Price & News

$10.03
+0.03 (+0.30%)
(As of 12/1/2021 04:25 PM ET)
Add
Compare
Today's Range
$10.03
$10.15
50-Day Range
$9.90
$12.00
52-Week Range
$8.48
$14.89
Volume
29 shs
Average Volume
74,414 shs
Market Capitalization
$132.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.49
30 days | 90 days | 365 days | Advanced Chart
Receive KZIA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Kazia Therapeutics logo

About Kazia Therapeutics

Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Headlines

GBM AGILE Opens to Paxalisib in Canada
November 29, 2021 |  finance.yahoo.com
PNOC Study in Childhood Brain Cancer Enrols First Patient
November 11, 2021 |  finance.yahoo.com
Kazia Therapeutics to Present at LD Micro Main Event
October 6, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZIA
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
$11.35 million
Book Value
$2.14 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
13,069,000
Market Cap
$132.41 million
Optionable
Not Optionable

Company Calendar

Today
12/01/2021
Next Earnings (Estimated)
1/06/2022
Fiscal Year End
6/30/2022

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

1036th out of 1,392 stocks

Pharmaceutical Preparations Industry

491st out of 669 stocks

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Kazia Therapeutics (NASDAQ:KZIA) Frequently Asked Questions

Is Kazia Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kazia Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kazia Therapeutics stock.
View analyst ratings for Kazia Therapeutics
or view top-rated stocks.

How has Kazia Therapeutics' stock been impacted by COVID-19?

Kazia Therapeutics' stock was trading at $3.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KZIA shares have increased by 152.0% and is now trading at $10.03.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Kazia Therapeutics?

Kazia Therapeutics saw a drop in short interest during the month of October. As of October 29th, there was short interest totaling 2,300 shares, a drop of 37.8% from the October 14th total of 3,700 shares. Based on an average trading volume of 26,300 shares, the days-to-cover ratio is presently 0.1 days.
View Kazia Therapeutics' Short Interest
.

When is Kazia Therapeutics' next earnings date?

Kazia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, January 6th 2022.
View our earnings forecast for Kazia Therapeutics
.

What price target have analysts set for KZIA?

2 analysts have issued 12-month price objectives for Kazia Therapeutics' shares. Their forecasts range from $17.00 to $18.00. On average, they expect Kazia Therapeutics' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 74.5% from the stock's current price.
View analysts' price targets for Kazia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Kazia Therapeutics' key executives?

Kazia Therapeutics' management team includes the following people:
  • James Garner, Chief Executive Officer, Executive Director & MD
  • Gabrielle Heaton, Director-Finance & Administration
  • Catherine Hill, Secretary

What other stocks do shareholders of Kazia Therapeutics own?

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

Who are Kazia Therapeutics' major shareholders?

Kazia Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (2.18%), SG Americas Securities LLC (0.30%), Renaissance Technologies LLC (0.19%) and Total Clarity Wealth Management Inc. (0.04%).

Which major investors are selling Kazia Therapeutics stock?

KZIA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and SG Americas Securities LLC.

Which major investors are buying Kazia Therapeutics stock?

KZIA stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, and Total Clarity Wealth Management Inc..

How do I buy shares of Kazia Therapeutics?

Shares of KZIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kazia Therapeutics' stock price today?

One share of KZIA stock can currently be purchased for approximately $10.03.

How much money does Kazia Therapeutics make?

Kazia Therapeutics has a market capitalization of $132.41 million and generates $11.35 million in revenue each year.

How many employees does Kazia Therapeutics have?

Kazia Therapeutics employs 2,021 workers across the globe.

What is Kazia Therapeutics' official website?

The official website for Kazia Therapeutics is www.kaziatherapeutics.com.

Where are Kazia Therapeutics' headquarters?

How can I contact Kazia Therapeutics?

Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company can be reached via phone at (129) 472-4101, via email at [email protected], or via fax at 61-2-9476-0388.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.